Switch theme
Sign up to access all valuation multiples
Attana AB offers biologically relevant information to improve efficiency and performance of pharmaceutical drug development.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Attana has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Attana achieved revenue of $0.4M and an EBITDA of -$0.5M.
Attana expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Attana valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.5M | $0.4M | XXX | XXX | XXX |
| Gross Profit | $0.8M | $0.6M | XXX | XXX | XXX |
| Gross Margin | 147% | 136% | XXX | XXX | XXX |
| EBITDA | -$1.0M | -$0.5M | XXX | XXX | XXX |
| EBITDA Margin | -201% | -110% | XXX | XXX | XXX |
| Net Profit | -$1.5M | -$1.4M | XXX | XXX | XXX |
| Net Margin | -290% | -336% | XXX | XXX | XXX |
| Net Debt | $0.3M | $0.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 15, 2025, Attana's stock price is SEK 0 (or $0).
Attana has current market cap of SEK 35.9M (or $3.7M), and EV of SEK 37.0M (or $3.8M).
See Attana trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.8M | $3.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 15, 2025, Attana has market cap of $3.7M and EV of $3.8M.
Attana's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Attana's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Attana and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.8M | XXX | XXX | XXX |
| EV/Revenue | 9.0x | XXX | XXX | XXX |
| EV/EBITDA | -8.2x | XXX | XXX | XXX |
| P/E | -2.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -7.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAttana's NTM/LTM revenue growth is n/a
Attana's revenue per employee for the last fiscal year averaged $42K, while opex per employee averaged n/a for the same period.
Over next 12 months, Attana's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Attana's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Attana and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -19% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | -55% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | $42K | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 4% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Attana acquired XXX companies to date.
Last acquisition by Attana was XXXXXXXX, XXXXX XXXXX XXXXXX . Attana acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Attana founded? | Attana was founded in 2002. |
| Where is Attana headquartered? | Attana is headquartered in Sweden. |
| How many employees does Attana have? | As of today, Attana has 10 employees. |
| Is Attana publicy listed? | Yes, Attana is a public company listed on NGM. |
| What is the stock symbol of Attana? | Attana trades under ATANA ticker. |
| When did Attana go public? | Attana went public in 2018. |
| Who are competitors of Attana? | Similar companies to Attana include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Attana? | Attana's current market cap is $3.7M |
| What is the current revenue growth of Attana? | Attana revenue growth between 2023 and 2024 was -19%. |
| Is Attana profitable? | Yes, Attana is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
